{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:02Z","timestamp":1792592342795,"version":"4.5.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102565","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T02:42:54Z","timestamp":1748054574000},"page":"102565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Unmet needs in autoimmune liver diseases"],"prefix":"10.1016","volume":"95","author":[{"given":"Mirjam","family":"Kolev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Sokollik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merill Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Terziroli Beretta-Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bobzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ynto","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"de Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Deganello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lanzavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mitchell-Thain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcnz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Samyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Salvioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102565_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaip.2020.10.057","article-title":"Patterns of immune dysregulation in primary immunodeficiencies: a systematic review","volume":"9","author":"Mauracher","year":"2021","journal-title":"J Allergy Clin Immunol Pr"},{"key":"10.1016\/j.coi.2025.102565_bib2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS phenotypical classification for human inborn errors of immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb1662","article-title":"Human inborn errors of immunity: an expanding universe","volume":"5","author":"Notarangelo","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2025.102565_sbref4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/hep.32539","article-title":"Tip of the iceberg: a comprehensive review of liver disease in inborn errors of immunity","volume":"76","author":"Sharma","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s12016-017-8638-z","article-title":"Common variable immunodeficiency and liver involvement","volume":"55","author":"Song","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-021-08871-4","article-title":"Precision medicine in the treatment of primary immune deficiency patients with disorders of immune dysregulation","volume":"63","author":"Ballow","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.980768","article-title":"HLA, gut microbiome and hepatic autoimmunity","volume":"13","author":"Terziroli Beretta-Piccoli","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/hep.1840190311","article-title":"Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis","volume":"19","author":"Doherty","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib9","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.31893","article-title":"Human leukocyte antigen profile predicts severity of autoimmune liver disease in children of European ancestry","volume":"74","author":"Ma","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.gastro.2014.06.020","article-title":"Genetic risks link autoimmune hepatitis to other autoimmune liver disease","volume":"147","author":"Hirschfield","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_sbref11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","article-title":"Genome-wide association study identifies variants associated with autoimmune hepatitis type 1","volume":"147","author":"de Boer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/gene.2014.82","article-title":"HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1","volume":"16","author":"van Gerven","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.coi.2025.102565_bib13","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/onc.2012.435","article-title":"Role of the adaptor protein LNK in normal and malignant hematopoiesis","volume":"32","author":"Gery","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.coi.2025.102565_sbref14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.32417","article-title":"Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1","volume":"76","author":"Li","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264307","article-title":"Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management","volume":"17","author":"Tana","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102565_bib16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1176\/ajp.149.10.1407b","article-title":"Bupropion-induced carbohydrate craving and weight gain","volume":"149","author":"Workman","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.coi.2025.102565_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(04)15541-4","article-title":"Frequency of monosomy X in women with primary biliary cirrhosis","volume":"363","author":"Invernizzi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102565_bib18","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis","volume":"42","author":"Liu","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102565_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/gene.2012.17","article-title":"Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis","volume":"13","author":"Invernizzi","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.coi.2025.102565_sbref21","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1053\/j.gastro.2021.02.061","article-title":"X chromosome contribution to the genetic architecture of primary biliary cholangitis","volume":"160","author":"Asselta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-021-03243-6","article-title":"Improving reporting standards for polygenic scores in risk prediction studies","volume":"591","author":"Wand","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102565_bib23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00439-021-02387-9","article-title":"Interpretable machine learning for genomics","volume":"141","author":"Watson","year":"2022","journal-title":"Hum Genet"},{"key":"10.1016\/j.coi.2025.102565_bib24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrg3604","article-title":"Recent human adaptation: genomic approaches, interpretation and insights","volume":"14","author":"Scheinfeldt","year":"2013","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coi.2025.102565_bib25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cgh.2008.03.016","article-title":"Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis","volume":"6","author":"Bergquist","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00003086-199101000-00012","article-title":"Pulmonary metastases and bone sarcomas. Surgical removal of lesions appearing after adjuvant chemotherapy","volume":"262","author":"Burk","year":"1991","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.coi.2025.102565_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","article-title":"Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci","volume":"43","author":"Melum","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102565_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.gene.6364377","article-title":"Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis","volume":"8","author":"Karlsen","year":"2007","journal-title":"Genes Immun"},{"key":"10.1016\/j.coi.2025.102565_bib29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/hep.24333","article-title":"Genome-wide association studies in primary sclerosing cholangitis: still more questions than answers?","volume":"53","author":"Chapman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/hep.24299","article-title":"Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis","volume":"53","author":"Hov","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib31","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/lt.22161","article-title":"Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations","volume":"16","author":"Bowlus","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.coi.2025.102565_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2616","article-title":"Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis","volume":"45","author":"Liu","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102565_bib33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102565_sbref34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.3745","article-title":"Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease","volume":"49","author":"Ji","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102565_bib35","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","article-title":"Genome-wide association analysis in primary sclerosing cholangitis","volume":"138","author":"Karlsen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/00365521.2012.682090","article-title":"Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis","volume":"47","author":"Srivastava","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci","volume":"57","author":"Folseraas","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.25977","article-title":"Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4","volume":"58","author":"Ellinghaus","year":"2013","journal-title":"Hepatology"},{"issue":"562","key":"10.1016\/j.coi.2025.102565_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.aau9048","article-title":"GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump","volume":"12","author":"Schneditz","year":"2019","journal-title":"Sci Signal"},{"issue":"582","key":"10.1016\/j.coi.2025.102565_sbref40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1126\/scitranslmed.abb0036","article-title":"A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis","volume":"13","author":"Jiang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102565_bib41","article-title":"The prevalence of autoimmune disorders in women: a narrative review","volume":"12","author":"Angum","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2025.102565_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41423-018-0018-y","article-title":"The long and latent road to autoimmunity","volume":"15","author":"Selmi","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102565_sbref43","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: what is new and what needs to be done","volume":"105","author":"Terziroli Beretta-Piccoli","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.32172","article-title":"E. coli and the etiology of human PBC: antimitochondrial antibodies and spreading determinants","volume":"75","author":"Yang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms7120583","article-title":"The Th17\/Treg cell balance: a gut microbiota-modulated story","volume":"7","author":"Cheng","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.coi.2025.102565_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.coi.2025.102565_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15869","article-title":"Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis","volume":"8","author":"Savola","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102565_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coi.2011.12.003","article-title":"Autoantigenesis: the evolution of protein modifications in autoimmune disease","volume":"24","author":"Doyle","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.01853","article-title":"The infectious basis of ACPA-positive rheumatoid arthritis","volume":"8","author":"Sakkas","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coi.2025.102565_bib52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10620-011-1993-3","article-title":"Primary biliary cirrhosis: bad genes, bad luck","volume":"57","author":"Invernizzi","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coi.2025.102565_bib53","first-page":"160","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coi.2025.102565_bib54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102565_bib55","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2","volume":"205","author":"Lunemann","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102565_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coi.2025.102565_bib57","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102565_bib58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102565_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2025.102565_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/eji.202048655","article-title":"Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15","volume":"51","author":"Zdimerova","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib61","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coi.2025.102565_bib62","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib63","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/BF01537282","article-title":"Autoimmune chronic active hepatitis developing after acute type B hepatitis","volume":"34","author":"Laskus","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coi.2025.102565_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2006.111864","article-title":"Autoimmune hepatitis triggered by hepatitis A","volume":"56","author":"Singh","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_sbref65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1056\/NEJMc2311867","article-title":"JAK inhibition in STAT1 gain-of-function-mediated treatment-resistant autoimmune hepatitis","volume":"390","author":"Hadzic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_sbref66","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib67","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011621","article-title":"Autoimmune hepatitis following influenza virus vaccination: two case reports","volume":"97","author":"Sasaki","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2025.102565_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102706","article-title":"Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity?","volume":"123","author":"Ghielmetti","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0016-5085(95)90074-8","article-title":"Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection","volume":"108","author":"Durazzo","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib70","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2021.02.006","article-title":"Primary biliary cholangitis associated with SARS-CoV-2 infection","volume":"74","author":"Bartoli","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib71","article-title":"De novo autoimmune hepatitis after COVID-19 infection in an unvaccinated patient","volume":"2022","author":"Durazo","year":"2022","journal-title":"Case Rep Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib72","article-title":"SARS-CoV-2-Induced autoimmune hepatitis","volume":"15","author":"Martini","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2025.102565_bib73","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s42255-022-00552-6","article-title":"Molecular consequences of SARS-CoV-2 liver tropism","volume":"4","author":"Wanner","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.coi.2025.102565_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm11102681","article-title":"COVID-19 and autoimmune liver diseases","volume":"11","author":"Floreani","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2025.102565_bib75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2022.02.013","article-title":"Autoimmune hepatitis and COVID-19: no increased risk for AIH after vaccination but reduced care","volume":"77","author":"Ruther","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib76","article-title":"Histological and serological features of acute liver injury after SARS-CoV-2 vaccination","volume":"5","author":"Codoni","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coi.2025.102565_bib77","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.32572","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","volume":"76","author":"Efe","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib78","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jhep.2022.03.040","article-title":"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis","volume":"77","author":"Boettler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_sbref79","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2023.05.020","article-title":"Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics","volume":"79","author":"Uzun","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/liv.16209","article-title":"Autoimmune-like hepatitis related to SARS-CoV-2 vaccination: towards a clearer definition","volume":"45","author":"Efe","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib81","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"de Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib82","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/liv.15623","article-title":"Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries","volume":"43","author":"Garcia-Cortes","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/liv.15378","article-title":"A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry","volume":"43","author":"Bjornsson","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib84","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib85","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Bjornsson","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.coi.2025.102565_bib86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib87","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib88","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib89","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.coi.2025.102565_sbref90","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.coi.2025.102565_bib91","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib92","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coi.2025.102565_bib93","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","article-title":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: position statement of the AEEH-AEG-SEPD-SEOM-GETECCU","volume":"47","author":"Riveiro-Barciela","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib94","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.15340","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort","volume":"43","author":"Berry","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib96","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.coi.2025.102565_bib97","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.coi.2025.102565_bib98","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_sbref99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_sbref100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib102","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib103","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(66)92131-3","article-title":"Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells","volume":"1","author":"Whittingham","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102565_bib104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jcp.29.5.403","article-title":"Classification of smooth muscle autoantibodies detected by immunofluorescence","volume":"29","author":"Bottazzo","year":"1976","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.coi.2025.102565_bib105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/0891693021000054066","article-title":"Smooth muscle antibodies and type 1 autoimmune hepatitis","volume":"35","author":"Muratori","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.coi.2025.102565_bib106","first-page":"331","article-title":"Microsomal antibodies in active chronic hepatitis and other disorders","volume":"15","author":"Rizzetto","year":"1973","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib107","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1084\/jem.168.2.801","article-title":"Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily","volume":"168","author":"Gueguen","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102565_bib108","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1073\/pnas.85.21.8256","article-title":"Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II","volume":"85","author":"Zanger","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102565_bib109","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI113949","article-title":"Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1","volume":"83","author":"Manns","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102565_bib110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.46.4.553","article-title":"Liver\/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane","volume":"46","author":"Muratori","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib111","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.1840080632","article-title":"Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2","volume":"8","author":"Martini","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib112","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0016-5085(99)70186-1","article-title":"Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis","volume":"116","author":"Lapierre","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib113","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib114","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMcpc0807822","article-title":"Case records of the Massachusetts General Hospital. Case 5-2009. A 47-year-old woman with a rash and numbness and pain in the legs","volume":"360","author":"Kroshinsky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib115","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: an old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102565_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94754-9","article-title":"Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease","volume":"11","author":"Janowski","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102565_bib117","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11547-020-01301-z","article-title":"The role of point of care ultrasound in radiology department: update and prospective. A statement of Italian college ultrasound","volume":"126","author":"Di Serafino","year":"2021","journal-title":"Radio Med"},{"key":"10.1016\/j.coi.2025.102565_bib118","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2015142815","article-title":"Feasibility and diagnostic accuracy of supersonic shear-wave elastography for the assessment of liver stiffness and liver fibrosis in children: a pilot study of 96 patients","volume":"278","author":"Franchi-Abella","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.coi.2025.102565_bib119","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00247-020-04959-9","article-title":"Diagnostic accuracy of two-dimensional shear wave elastography in detecting hepatic fibrosis in children with autoimmune hepatitis, biliary atresia and other chronic liver diseases","volume":"51","author":"Galina","year":"2021","journal-title":"Pedia Radio"},{"key":"10.1016\/j.coi.2025.102565_bib120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0042-117226","article-title":"Shear wave elastography of the liver - review on normal values","volume":"55","author":"Dong","year":"2017","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib121","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MEG.0000000000001702","article-title":"Performance and cutoffs for liver fibrosis staging of a two-dimensional shear wave elastography technique","volume":"33","author":"Ferraioli","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib122","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221140657","article-title":"Update on the role of elastography in liver disease","volume":"15","author":"Ferraioli","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib123","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.rcl.2022.05.007","article-title":"MR imaging in primary sclerosing cholangitis and other cholangitis","volume":"60","author":"O'Brien","year":"2022","journal-title":"Radio Clin North Am"},{"key":"10.1016\/j.coi.2025.102565_sbref124","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00330-021-08147-7","article-title":"Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group","volume":"32","author":"Venkatesh","year":"2022","journal-title":"Eur Radio"},{"key":"10.1016\/j.coi.2025.102565_bib125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00247-008-0918-6","article-title":"Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography","volume":"38","author":"Chavhan","year":"2008","journal-title":"Pedia Radio"},{"key":"10.1016\/j.coi.2025.102565_bib126","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2214\/AJR.21.26423","article-title":"Agreement between automated and clinically reported manual ROI-based MR elastography liver stiffness measurements in children and young adults","volume":"218","author":"Dillman","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.coi.2025.102565_bib127","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jmri.27113","article-title":"Quantitative MRCP imaging: accuracy, repeatability, reproducibility, and cohort-derived normative ranges","volume":"52","author":"Goldfinger","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.coi.2025.102565_sbref128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_sbref129","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib130","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib131","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib132","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib133","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib134","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102565_bib135","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib136","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.coi.2025.102565_bib137","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_sbref138","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib140","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","article-title":"Human gut bacteria produce Tau(Eta)17-modulating bile acid metabolites","volume":"603","author":"Paik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102565_bib141","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib142","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_sbref143","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib144","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/apt.17251","article-title":"Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis","volume":"57","author":"Bogatic","year":"2023","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.coi.2025.102565_bib145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib146","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39029-9","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102565_sbref147","article-title":"Medical treatment of primary sclerosing cholangitis: what have we learned and where are we going?","author":"Karlsen","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib148","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41423-021-00768-8","article-title":"Autoimmmune hepatitis","volume":"19","author":"Terziroli Beretta-Piccoli","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib149","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib150","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"Wendon","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib151","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib152","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/HEP.0000000000000940","article-title":"Optimizing thiopurine therapy in autoimmune hepatitis: a multicenter study on monitoring metabolite profiles and co-therapy with allopurinol","volume":"80","author":"Weltzsch","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib153","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib154","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib155","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103113","article-title":"Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis","volume":"140","author":"Terziroli Beretta-Piccoli","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib157","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/liv.15440","article-title":"Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey","volume":"43","author":"Wunsch","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib158","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib159","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","article-title":"Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis","volume":"25","author":"Longhi","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_sbref160","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102565_bib161","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.22914","article-title":"Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells","volume":"50","author":"Longhi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib162","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.23792","article-title":"A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis","volume":"52","author":"Ferri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib163","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaut.2012.12.003","article-title":"T-regs in autoimmune hepatitis-systemic lupus erythematosus\/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile","volume":"41","author":"Longhi","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib164","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.26583","article-title":"Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis","volume":"59","author":"Grant","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_sbref166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI183776","article-title":"Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis","volume":"135","author":"Kramer","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102565_bib167","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","article-title":"Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis","volume":"47","author":"Longhi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib168","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","article-title":"Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis","volume":"142","author":"Longhi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102565_bib169","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hep.24039","article-title":"Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis","volume":"53","author":"Longhi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102565_bib171","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for Refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib172","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib173","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3748\/wjg.15.2049","article-title":"Intrahepatic cholestasis of pregnancy","volume":"15","author":"Geenes","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib174","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib175","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.14579","article-title":"Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study","volume":"47","author":"Webb","year":"2018","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.coi.2025.102565_bib176","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib177","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102565_bib178","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/MPG.0000000000000672","article-title":"Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease","volume":"60","author":"Pusateri","year":"2015","journal-title":"J Pedia Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102565_sbref179","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/liv.14159","article-title":"Disease progression in paediatric- and adult-onset sclerosing cholangitis: results from two independent Dutch registries","volume":"39","author":"Joosse","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_sbref181","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2023.02.030","article-title":"Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?","volume":"79","author":"Ricciuto","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib182","doi-asserted-by":"crossref","DOI":"10.57187\/smw.2023.40102","article-title":"Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study","volume":"153","author":"Ludz","year":"2023","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.coi.2025.102565_bib183","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2020.04.055","article-title":"Colorectal dysplasia and cancer in pediatric-onset ulcerative colitis associated with primary sclerosing cholangitis","volume":"19","author":"El-Matary","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib184","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2019.11.028","article-title":"Seamless management of juvenile autoimmune liver disease: long-term medical and social outcome","volume":"218","author":"Di Giorgio","year":"2020","journal-title":"J Pedia"},{"key":"10.1016\/j.coi.2025.102565_bib185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MPG.0000000000003513","article-title":"Long-term growth in children and young people with autoimmune liver disease treated with daily steroids","volume":"75","author":"Manwani","year":"2022","journal-title":"J Pedia Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102565_bib186","unstructured":"Body Image Report \u3008https:\/\/www.mentalhealth.org.uk\/explore-mental-health\/articles\/body-image-report-executive-summary\u3009 2024."},{"key":"10.1016\/j.coi.2025.102565_bib187","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.2007.03001.x","article-title":"Muscular exercise can cause highly pathological liver function tests in healthy men","volume":"65","author":"Pettersson","year":"2008","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.coi.2025.102565_bib188","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000003119","article-title":"Adherence, mental health and illness perceptions in autoimmune liver disease: looking beyond liver function tests","volume":"73","author":"Hames","year":"2021","journal-title":"J Pedia Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102565_bib189","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2016.11.013","article-title":"The management of childhood liver diseases in adulthood","volume":"66","author":"Joshi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib190","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/hep.32410","article-title":"Autoimmune hepatitis in pregnancy: pearls and pitfalls","volume":"76","author":"Chung","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib191","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41395-018-0181-x","article-title":"Non-invasive markers (ALBI and APRI) predict pregnancy outcomes in women with chronic liver disease","volume":"114","author":"Gonsalkorala","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7303a1","article-title":"U.S. Selected Practice Recommendations for Contraceptive Use, 2024","volume":"73","author":"Curtis","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.coi.2025.102565_bib193","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/ajcn\/nqy065","article-title":"Modeling the impact of folic acid fortification and supplementation on red blood cell folate concentrations and predicted neural tube defect risk in the United States: have we reached optimal prevention?","volume":"107","author":"Crider","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.coi.2025.102565_bib194","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2025.102565_bib195","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.31559","article-title":"Reproductive health and liver disease: practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Sarkar","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib196","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib197","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ajg.2015.430","article-title":"ACG clinical guideline: liver disease and pregnancy","volume":"111","author":"Tran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib198","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/liv.12901","article-title":"Increased risk of preterm birth in women with autoimmune hepatitis - a nationwide cohort study","volume":"36","author":"Stokkeland","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2025.102565_bib199","doi-asserted-by":"crossref","first-page":"J239","DOI":"10.1016\/j.jaut.2011.12.002","article-title":"Outcomes of pregnancy in women with autoimmune hepatitis","volume":"38","author":"Westbrook","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCG.0b013e318176b8c5","article-title":"Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes","volume":"43","author":"Terrabuio","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M14-1884","article-title":"Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2025.102565_bib202","unstructured":"Inderal."},{"key":"10.1016\/j.coi.2025.102565_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102651","article-title":"T helper cell immunity in pregnancy and influence on autoimmune disease progression","volume":"121","author":"Graham","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102565_bib204","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/00365520601155266","article-title":"Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?","volume":"42","author":"Werner","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_sbref203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.32132","article-title":"Outcomes of pregnancy in autoimmune hepatitis: a population-based study","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102565_bib206","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1572-0241.2006.00479.x","article-title":"Pregnancy in autoimmune hepatitis: outcome and risk factors","volume":"101","author":"Schramm","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102565_bib207","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/gut.48.1.97","article-title":"Management and outcome of pregnancy in autoimmune hepatitis","volume":"48","author":"Heneghan","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib208","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinimag.2021.01.006","article-title":"Pediatric biliary disorders: multimodality imaging evaluation with clinicopathologic correlation","volume":"75","author":"Aboughalia","year":"2021","journal-title":"Clin Imaging"},{"key":"10.1016\/j.coi.2025.102565_bib209","article-title":"Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis","volume":"6","author":"Nayagam","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coi.2025.102565_bib210","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/gut.2010.228924","article-title":"Pregnancy in primary sclerosing cholangitis","volume":"60","author":"Wellge","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib211","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1471-0528.16119","article-title":"Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study","volume":"127","author":"Cauldwell","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.coi.2025.102565_bib212","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2014.05.008","article-title":"Pregnancy in women with primary biliary cirrhosis","volume":"13","author":"Efe","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102565_bib213","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cgh.2013.11.030","article-title":"Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis","volume":"12","author":"Trivedi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib214","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2019.08.020","article-title":"Ursodeoxycholic acid in pregnancy?","volume":"71","author":"de Vries","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102565_bib215","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102565_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)01016-4","article-title":"Non-adherence to standard pharmacotherapy in autoimmune hepatitis is associated with over-the-counter medication and steroid treatment. Results from the ERN online survey","volume":"78","author":"Wunsch","year":"2023","journal-title":"J Hepatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:06:49Z","timestamp":1779084409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152500041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":216,"alternative-id":["S095279152500041X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102565","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in autoimmune liver diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102565"}}